Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER

NCT04872608 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT04872608
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04872608 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ctDNA-guided Adaptive Therapy Escalation in ER+ MBC: A Phase 1b Study With Letrozole, Palbociclib and Onapristone ER
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 1
Overall status
Withdrawn
Start date
September 9, 2021
Completion date
April 25, 2023
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, unresectable breast cancer